| Identification | Back Directory | [Name]
2-[(4R)-4-[(5-ethylsulfonyl-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl]-5,5,5-trifluoro-4-hydroxy-2-methylpentan-2-yl]-5-fluorobenzamide | [CAS]
1198784-72-3 | [Synonyms]
2-[(4R)-4-[(5-ethylsulfonyl-1H-pyrrolo[2,3-c]pyridin-2-yl)methyl]-5,5,5-trifluoro-4-hydroxy-2-methylpentan-2-yl]-5-fluorobenzamide | [Molecular Formula]
C23H25F4N3O4S | [MDL Number]
MFCD34469110 | [MOL File]
1198784-72-3.mol | [Molecular Weight]
515.521 |
| Hazard Information | Back Directory | [Uses]
BI 653048 is a selective and orally active nonsteroidal?glucocorticoid (GC)?agonist with an IC50 value of 55 nM[1]. BI 653048 inhibits CP1A2, CYP2D6, CYP2C9, CYP2C19 and CYP3A4 isoforms’ activity and reduces affinity for the hERG ion channel (IC50>30 μM)[2]. BI 653048 is extracted from patent WO2005028501A1 (Compound 103), is also a?HCV NS3 protease?inhibitor that can reduce viral loads infected with the?hepatitis C?virus[3]. | [in vivo]
BI 653048 (oral administration; 3, 10, and 30 mg/kg) at 3 mg/kg has nonsignificant decreases for all measured histology parameters (ankle inflammation, pannus formation, cartilage damage, and bone resorption), Mid-dose (10 mg/kg) treatment significantly decreases pannus and bone resorption (33%) as well as summed scores (27%), while at high dose (30 mg/kg), all parameters are significantly decreased (87–96%). The ED50 value for the summed scores is 14 mg/kg[2]. | Animal Model: | Mice[2] | | Dosage: | 3, 10, and 30 mg/kg | | Administration: | Oral administration | | Result: | Exhibits significant decreases for all measured histology parameters at high doses. |
| [IC 50]
CYP1A2: 50 μM (IC50); CYP2D6: 41 μM (IC50); CYP2C9: 12 μM (IC50); CYP2C19: 9 μM (IC50); CYP3A4: 8 μM (IC50) | [References]
[1] Reeves JT, et al. Development of a large scale asymmetric synthesis of the glucocorticoid agonist BI 653048 BS H3PO4.J Org Chem. 2013 Apr 19;78(8):3616-35. DOI:10.1021/jo400079z [2] Harcken C, et al. Optimization?of?drug-like?properties?of?nonsteroidal?glucocorticoid?mimetics?and?identification?of a?clinical?candidate.ACS Med Chem Lett.?2014 Nov 20;5(12):1318-23. DOI:10.1021/ml500387y [3] Montse Llinas-Brunet, et al. Latest bibliographic data on file with the International Bureau |
|
|